<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03831126</url>
  </required_header>
  <id_info>
    <org_study_id>PerFet_maternal_stress_fMEG</org_study_id>
    <nct_id>NCT03831126</nct_id>
  </id_info>
  <brief_title>Stress and Fetal Brain Development</brief_title>
  <official_title>The Impact of Stress on Fetal Brain Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current proposal aims to investigate the impact of acute stress on the fetal autonomic
      nervous system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over the last decades there is growing evidence that increased maternal stress levels lead to
      an adverse effect on the physiological, metabolic and neuronal development of the fetus
      during gestation with possible long-lasting effects. Several studies showed that maternal
      stress also affects fetal endocrine processes during pregnancy and increases the risk for
      childhood and adult obesity. Thus, the aim of the study is to investigate the effect of acute
      stress related to the action of the artificial glucocorticoid betamethasone on fetal heart
      and brain activity. The fetal activity will be measured with biomagnetic sensors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>fetal and maternal heart rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measurement by fMEG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fetal and neonatal brain activity in response to auditory and visual stimuli</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measurement by fMEG</description>
  </secondary_outcome>
  <other_outcome>
    <measure>blood sugar levels</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measurement by fMEG</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>betamethasone treatment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethason Sodium Phosphate</intervention_name>
    <description>First measurement: 12-36 hours after betamethasone treatment Second measurement: within five days after betamethasone treatment and two weeks Third measurement (neonatal measurement): 1-8 weeks after birh</description>
    <arm_group_label>betamethasone treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  German speakers (fluently)

          -  Gestational age between 28 and 34 weeks

          -  Treatment with Betamethasone for improvement of fetal lung function -

        Exclusion Criteria:

          -  Smoking (regularly)

          -  Alcohol and drug consumption during pregnancy

          -  Congenital fetal disorders

          -  Women with bed rest

          -  acute depression or other psychiatric disorder (self report)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jan Pauluschke-Fr√∂hlich, MD</last_name>
    <phone>07071 2983111</phone>
    <email>jan.pauluschke-froehlich@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Tuebingen, Department of Women's Health</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Linneweh, Dr</last_name>
      <phone>+4970712982211</phone>
      <email>miriam.linneweh@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>February 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

